Post-transplant cyclophosphamide (PTCy) is a chemotherapy used after hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GVHD), especially in haploidentical (half-matched) transplants, by selectively killing donor immune cells (T-cells) while sparing stem cells.
High expression of aldehyde dehydrogenase (ALDH) in stem cells and Tregs inactivates cyclophosphamide’s toxic metabolite, making them resistant.
Alloreactive T cells (proliferating post-transplant due to antigen stimulation) are preferentially eliminated via apoptosis.
Post-transplant cyclophosphamide (often abbreviated as PTCy or post-transplant cyclophosphamide) is a high-dose cyclophosphamide administered shortly after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to prevent graft-versus-host disease (GVHD).
It has revolutionized transplantation, particularly for patients without fully HLA-matched donors, by enabling safe use of haploidentical (half-matched, e.g., from a parent or child) or mismatched unrelated donors.
Administered on days 3 and 4 post-infusion, PTCy has made transplants from mismatched donors safer and more common, though managing its cardiac toxicities and balancing GVHD prevention with the graft-versus-tumor effect remain key clinical considerations.
Given shortly after transplant, PTCy targets rapidly dividing immune cells from the donor (T-cells) that cause GVHD, but it largely spares the hematopoietic stem cells needed for engraftment.
Its effectiveness allows transplants from donors with significant human leukocyte antigen (HLA) mismatches, expanding donor options.
It induces immune tolerance through mechanisms like selective depletion of alloreactive clones, promotion of Tregs, and induction of suppressive functions that prevent GVHD without broadly suppressing the immune system.
PTCy is a cornerstone of GVHD prophylaxis in haploidentical HSCT.
It is also used in HLA-matched transplants and with other conditioning regimens.
PTCy improves outcomes: Reduces severe GVHD, improving GVHD-free, relapse-free survival in some cases.
Cardiac Toxicity: Potential for heart problems (arrhythmias, heart failure) requires monitoring (ECG, Echo).
Infections: Associated with increased bacterial infections.
Balancing GVHD prevention with maintaining the GVT effect (donor cells fighting cancer) is crucial.
Dosing: adjustments may speed engraftment and reduce toxicity for bone marrow transplants.
Unlike traditional agents (e.g., calcineurin inhibitors like tacrolimus), PTCy promotes apoptosis in activated T cells and supports faster tolerance induction.
This selective effect allows engraftment while reducing severe GVHD, especially chronic forms.
PTCy is typically given at 50 mg/kg on days +3 and +4 post-transplant (total 100 mg/kg), often combined with other agents like tacrolimus and mycophenolate mofetil (PTCy/Tac/MMF).
It dramatically reduced GVHD rates, making haploidentical transplants standard-of-care with outcomes comparable to matched donors in many settings.
Trials show PTCy-based regimens (e.g., PTCy/Tac/MMF) reduce chronic GVHD and improve GVHD-free/relapse-free survival (GRFS) compared to traditional tacrolimus/methotrexate.
Recent advances: Expanded use in older adults (≥70 years), with better GVHD control and immunosuppression-free survival.
Comparisons show PTCy benefits in matched related donor settings with longer GVHD-free/relapse-free survival.
Lower-dose PTCy combined with low-dose anti-thymocyte globulin to reduce toxicity while maintaining efficacy in haploidentical settings.
Ongoing refinements for specific diseases (e.g., AML, Hodgkin lymphoma) and reduced-toxicity regimens.